Medidata launches Medidata Plus AI layer for clinical trial platform

  • Medidata, a Dassault Systèmes brand, launched Medidata Plus, an AI layer designed to scale AI use across clinical trial portfolios.
  • The product targets a shift from point AI tools to a unified platform approach across study build, data management, risk monitoring.
  • Medidata said the AI layer can cut study build timelines from weeks to hours through automation, including synthetic data for testing.
  • Medidata said its AI supported 80% of FDA novel drug approvals in 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dassault Systèmes SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230100PRIMZONEFULLFEED9766816) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.